Studiul urmareste evaluarea eficacitatii administrarii de nivolumab in asociere cu iplimumab sau chemoterapie comparativ cu chemoterapia simpla la pacientii cu cancer urotelial neoperabil si netratat.

Titlu Studiu

A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

Cod protocol: CA209-901

Numar EudraCT: 2016-003881-14

Sponsor: Bristol-Myers Squibb

Medicament de investigatie clinica: nivolumab

Medicament de investigatie clinica comparator: gemcitabine, cisplatin, carboplatin

Placebo: nu

International/National: international

Faza: III

Centre România

Cluj-Napoca, Romania, 400015

Craiova, Romania, 200347